m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00934)
Name
(2R)-1-(2,6-dimethylphenoxy)propan-2-amine
Synonyms
94991-73-8; (R)-1-(2,6-dimethylphenoxy)propan-2-amine; (2R)-1-(2,6-dimethylphenoxy)propan-2-amine; 2-Propanamine, 1-(2,6-dimethylphenoxy)-, (2R)-; CHEMBL147507; zlchem 1301; (R)-MEXILETINE; (R)-(-)-Mexiletine; AC1L47IL; SCHEMBL16082; BIDD:GT0498; ZINC20257; ZLE0076; DTXSID50241709; BDBM50135883; AKOS017529564; DB07129; AJ-08428; KB-209407; (2R)-1-(2,6-dimethylphenoxy)-2-propanamine; A821017; (R)-2-(2,6-Dimethyl-phenoxy)-1-methyl-ethylamine; UNII-1U511HHV4Z component VLPIATFUUWWMKC-SNVBAGLBSA-N
    Click to Show/Hide
Status
Investigative
Structure
Formula
C11H17NO
InChI
1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3/t10-/m1/s1
InChIKey
VLPIATFUUWWMKC-SNVBAGLBSA-N
PubChem CID
180621
TTD Drug ID
D03NLL
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Urokinase-type plasminogen activator (PLAU)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Urokinase-type plasminogen activator (PLAU) is a therapeutic target for (2R)-1-(2,6-dimethylphenoxy)propan-2-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (2R)-1-(2,6-dimethylphenoxy)propan-2-amine through regulating the expression of Urokinase-type plasminogen activator (PLAU). [1], [2]
References
Ref 1 METTL3 promotes colorectal cancer metastasis by stabilizing PLAU mRNA in an m6A-dependent manner. Biochem Biophys Res Commun. 2022 Jul 23;614:9-16. doi: 10.1016/j.bbrc.2022.04.141. Epub 2022 May 6.
Ref 2 Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa. J Med Chem. 2001 Aug 16;44(17):2753-71. doi: 10.1021/jm0100638.